Renal and Non-renal Excretion Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Renal and Non-renal Excretion. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Renal and Non-renal Excretion Indian Medical PG Question 1: A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?
- A. 120 hours
- B. 140-180 hours
- C. 1 half-life (40 hours)
- D. 80 hours (Correct Answer)
Renal and Non-renal Excretion Explanation: ***80 hours (2 half-lives)***- Current digoxin level is **4 ng/mL**, which is **twice the upper therapeutic limit** (2 ng/mL), causing toxicity with nausea and vomiting [1]- After **1 half-life (40 hours)**: concentration reduces to 2 ng/mL (upper therapeutic limit) [2]- After **2 half-lives (80 hours)**: concentration reduces to 1 ng/mL (mid-therapeutic range) [2]- **Clinical rationale**: While 2 ng/mL is technically within range, waiting for 2 half-lives ensures the level is comfortably in the **middle of the therapeutic window** (1 ng/mL), providing a **safer margin** before resuming treatment in a patient who just experienced toxicity- This conservative approach minimizes risk of recurrent toxicity, especially important given the patient's recent symptoms at 4 ng/mL*1 half-life (40 hours)*- After 1 half-life, digoxin level would be 2 ng/mL, which is at the **upper limit** of the therapeutic range- While technically within the therapeutic range, this leaves **minimal safety margin** in a patient who just experienced toxicity- Starting treatment immediately at this level carries higher risk of recurrent side effects*120 hours (3 half-lives)*- After 3 half-lives, the concentration would be **0.5 ng/mL**, which is **below the therapeutic range** (1-2 ng/mL)- This is overly conservative and would **unnecessarily delay** resumption of essential cardiac medication- Could lead to inadequate control of the underlying condition (heart failure or atrial fibrillation)*140-180 hours (3.5-4.5 half-lives)*- This would reduce digoxin to **0.25-0.35 ng/mL**, well below therapeutic levels- This **excessive delay** is not clinically justified and could worsen the patient's cardiac condition- No standard protocol recommends waiting this long before resuming digoxin therapy
Renal and Non-renal Excretion Indian Medical PG Question 2: Which of the following statements about the biodisposition of penicillins and cephalosporins is NOT accurate?
- A. Procaine penicillin G is used for intramuscular injection
- B. Nafcillin and ceftriaxone are eliminated mainly by biliary secretion
- C. Oral bioavailability is affected by lability to gastric acid
- D. Renal tubular reabsorption of beta-lactams is inhibited by probenecid (Correct Answer)
Renal and Non-renal Excretion Explanation: ***Renal tubular reabsorption of beta-lactams is inhibited by probenecid*** - Probenecid inhibits the **active tubular secretion** of beta-lactam antibiotics, not their reabsorption, thereby increasing their half-life and maintaining higher plasma concentrations [3]. - This interaction is clinically useful for prolonging the antibacterial effect of penicillins and cephalosporins. *Oral bioavailability is affected by lability to gastric acid* - Many early penicillins, such as **penicillin G**, are highly susceptible to degradation by stomach acid, leading to poor oral bioavailability [2]. - This necessitates their administration via intravenous or intramuscular routes, or the development of **acid-stable analogs** like penicillin V [2]. *Procaine penicillin G is used for intramuscular injection* - **Procaine penicillin G** is formulated for intramuscular injection to create a **depot effect**, allowing for slow absorption and prolonged therapeutic plasma concentrations. - The procaine component also acts as a **local anesthetic**, reducing the pain associated with a large-volume intramuscular injection [1]. *Nafcillin and ceftriaxone are eliminated mainly by biliary secretion* - **Nafcillin** and **ceftriaxone** are indeed notable among beta-lactam antibiotics for their significant elimination through the biliary tract. - This route of excretion makes them particularly useful in patients with **renal impairment**, as their elimination is less dependent on kidney function.
Renal and Non-renal Excretion Indian Medical PG Question 3: Which of the following is the MOST important factor determining whether a substance can be filtered at the glomerulus?
- A. Lipid solubility of the substance
- B. Molecular weight of the substance (Correct Answer)
- C. Binding capacity to albumin
- D. None of the options
Renal and Non-renal Excretion Explanation: ***Molecular weight of the substance***
- The **glomerular filtration barrier** acts as a size-selective filter, generally permeable to substances with a molecular weight less than 5,000-10,000 Daltons
- Larger molecules are typically restricted from filtration due to the **size exclusion** property of the glomerular basement membrane and podocyte slit diaphragms
- This is the **primary determinant** of whether a substance can be filtered at all, making it the most important factor among the given options
*Lipid solubility of the substance*
- **Lipid solubility** is more relevant for reabsorption and secretion in the renal tubules, particularly for passive diffusion across tubular cell membranes
- It has minimal direct influence on the initial filtration process at the glomerulus, which is primarily a **pressure-driven, size- and charge-selective ultrafiltration** process
- The glomerular capillary wall is not a lipid membrane barrier for the filtration process
*Binding capacity to albumin*
- Substances bound to **large plasma proteins** like albumin (molecular weight ~67,000 Daltons) cannot pass through the glomerular filtration barrier
- While important for determining the *free, filterable fraction* of a substance in plasma, the binding itself is secondary to the fundamental molecular weight/size restriction
- Only the **free (unbound) fraction** of a substance is available for filtration, and whether it filters depends primarily on its molecular weight
*None of the options*
- This option is incorrect because **molecular weight** is indeed the most critical factor among the given options for determining whether a substance can be filtered at the glomerulus
Renal and Non-renal Excretion Indian Medical PG Question 4: A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
- A. 20 liter/hr
- B. K is 0.0693
- C. 0.22 L/hr (Correct Answer)
- D. 0.02 L/hr
Renal and Non-renal Excretion Explanation: ***0.22 L/hr***
- To calculate clearance at steady state, we use the formula: **Clearance (Cl) = Dose Rate / Css** (steady-state plasma concentration).
- **Dose rate calculation**: 100 mg/kg × 70 kg × 2 doses/day = 14,000 mg/day = 583.33 mg/hr
- **Converting plasma concentration**: 1.9 mg/mL = 1900 mg/L
- **Clearance calculation**: Cl = 583.33 mg/hr ÷ 1900 mg/L = **0.307 L/hr**
- **Note**: The calculated value (0.307 L/hr) does not exactly match any option. The marked answer (0.22 L/hr) is the closest approximation among the given choices. This discrepancy may arise from rounding in the original question parameters or implicit assumptions about bioavailability/volume of distribution.
*0.02 L/hr*
- This value is approximately 15 times lower than the calculated clearance.
- Such low clearance would result in much higher plasma concentrations or require significantly lower dosing.
*20 liter/hr*
- This clearance is approximately 65 times higher than calculated, representing an unrealistically high value for this scenario.
- Such high clearance would result in very low plasma concentrations unless extremely high doses were administered.
*K is 0.0693*
- This represents the **elimination rate constant (k)**, calculated as k = 0.693/t1/2 = 0.693/10 hr = 0.0693 hr⁻¹.
- While mathematically correct for k, the question specifically asks for **clearance**, not the elimination rate constant.
- Clearance is related to k by: Cl = k × Vd (volume of distribution).
Renal and Non-renal Excretion Indian Medical PG Question 5: Free water clearance is decreased by?
- A. Furosemide
- B. Vinblastine
- C. Vincristine
- D. Chlorpropamide (Correct Answer)
Renal and Non-renal Excretion Explanation: ***Chlorpropamide***
- **Chlorpropamide** is a sulfonylurea oral hypoglycemic agent that is a **classic and well-documented cause of SIADH (Syndrome of Inappropriate Antidiuretic Hormone)**.
- **SIADH** leads to increased ADH secretion, causing increased water reabsorption in the collecting ducts and thus **decreased free water clearance**.
- Among the options listed, chlorpropamide is the **prototypical drug** associated with drug-induced SIADH in pharmacology teaching.
*Furosemide*
- **Furosemide** is a loop diuretic that inhibits the reabsorption of sodium and chloride in the **loop of Henle**.
- This disrupts the medullary concentration gradient and leads to increased excretion of water and electrolytes, thereby **increasing free water clearance**.
*Vinblastine*
- **Vinblastine** is a vinca alkaloid chemotherapeutic agent primarily used in cancer treatment.
- It does not significantly affect renal water handling or ADH secretion and does **not typically cause SIADH**.
*Vincristine*
- **Vincristine** is another vinca alkaloid chemotherapy drug that **can also cause SIADH** and decrease free water clearance.
- However, in the context of standard pharmacology teaching and board examinations, **chlorpropamide** is the more classical example emphasized for drug-induced SIADH and decreased free water clearance.
- Vincristine is primarily known for its **neurotoxicity** as a major side effect.
Renal and Non-renal Excretion Indian Medical PG Question 6: Major mechanism of transport of drugs across biological membranes is:
- A. Passive diffusion (Correct Answer)
- B. Facilitated diffusion
- C. Active transport
- D. Endocytosis
Renal and Non-renal Excretion Explanation: ***Passive diffusion***
- This is the **most common mechanism** for drug transport across biological membranes, especially for **lipid-soluble** drugs.
- It occurs down a **concentration gradient** and does not require energy or carrier proteins.
*Facilitated diffusion*
- This process requires **carrier proteins** to move drugs across membranes, but it still occurs down a **concentration gradient** and does not consume energy directly.
- It handles substances that are **too large or too polar** to cross by passive diffusion, but it is not the primary mechanism for most drugs.
*Active transport*
- This mechanism uses **carrier proteins** and **expends energy (ATP)** to move drugs against their **concentration gradient**.
- It is important for the transport of specific drugs, but it is not the predominant mode for the majority of drug molecules.
*Endocytosis*
- This involves the **engulfment of large molecules** or particles by the cell membrane, forming vesicles.
- It is a less common mechanism for drug absorption, primarily used for **very large molecules** like proteins or nanoparticles.
Renal and Non-renal Excretion Indian Medical PG Question 7: Bile salts undergo conjugation for enhanced solubility:
- A. After conjugation with derived proteins
- B. After conjugation with lysine
- C. After conjugation with taurine and glycine (Correct Answer)
- D. After conjugation with betaglucuronic acid
Renal and Non-renal Excretion Explanation: ***After conjugation with taurine and glycine***
- This statement accurately describes the most common conjugation pathway for bile acids, increasing their **amphipathic properties** and solubility.
- Conjugation with these amino acids forms **bile salts** (e.g., glycocholate, taurocholate), which are essential for **micelle formation** and fat digestion.
- This is the primary mechanism by which bile acids become bile salts with enhanced solubility.
*After conjugation with betaglucuronic acid*
- While bile acids do undergo conjugation for increased solubility, they are primarily conjugated with glycine or taurine, not beta-glucuronic acid.
- Conjugation with beta-glucuronic acid is a common detoxification pathway for many xenobiotics and bilirubin, but not the primary method for bile acids.
*After conjugation with derived proteins*
- Bile salts are primarily steroid derivatives and are not conjugated with derived proteins.
- The purpose of conjugation is to increase hydrophilicity, which proteins would not achieve in this context.
*After conjugation with lysine*
- Lysine is an amino acid but is not involved in the conjugation of bile acids.
- Bile acid conjugation specifically uses the amino acids glycine and taurine.
Renal and Non-renal Excretion Indian Medical PG Question 8: In which of the following conditions is digoxin most likely to accumulate to toxic levels?
- A. Renal insufficiency (Correct Answer)
- B. Chronic hepatitis
- C. Advanced cirrhosis
- D. Chronic pancreatitis
Renal and Non-renal Excretion Explanation: ***Renal insufficiency***
- **Digoxin** is primarily excreted unchanged by the **kidneys**, so impaired renal function significantly prolongs its half-life and leads to drug accumulation.
- Patients with kidney failure require **dose adjustments** or closer monitoring of **digoxin levels** to prevent toxicity.
*Chronic hepatitis*
- **Chronic hepatitis** primarily affects the **liver's metabolic capacity**, which is not the primary route of **digoxin elimination**.
- While severe hepatic dysfunction can subtly impact drug disposition, it's not the main reason for **digoxin accumulation** like **renal insufficiency**.
*Advanced cirrhosis*
- **Advanced cirrhosis** involves severe liver dysfunction, which can alter drug metabolism and protein binding.
- However, **digoxin's elimination** is mainly renal, so liver disease alone does not typically lead to significant accumulation unless accompanied by **renal impairment**.
*Chronic pancreatitis*
- **Chronic pancreatitis** is a disorder of the pancreas and does not directly impact the **excretion or metabolism** of **digoxin**.
- It would not be expected to cause **digoxin accumulation** to toxic levels.
Renal and Non-renal Excretion Indian Medical PG Question 9: Which of the following is the primary mechanism that drives sodium reabsorption in the proximal tubule?
- A. Sodium reabsorption through cotransport with amino acids at the luminal membrane.
- B. Sodium reabsorption through cotransport with glucose at the luminal membrane.
- C. Sodium reabsorption through countertransport with hydrogen ions at the luminal membrane.
- D. Active sodium transport via the Na+-K+-ATPase pump at the basolateral membrane. (Correct Answer)
Renal and Non-renal Excretion Explanation: ***Active sodium transport via the Na+-K+-ATPase pump at the basolateral membrane.***
- This pump **actively transports sodium out of the cell** into the interstitial fluid, creating a low intracellular sodium concentration.
- The **Na+-K+-ATPase** is the primary driver of sodium reabsorption throughout the nephron, creating the electrochemical gradient for other sodium transporters.
*Sodium reabsorption through cotransport with amino acids at the luminal membrane.*
- While **sodium-amino acid cotransport** does occur in the proximal tubule, it accounts for only a fraction of total sodium reabsorption.
- The primary driving force for this cotransport is the **low intracellular sodium concentration** maintained by the Na+-K+-ATPase.
*Sodium reabsorption through cotransport with glucose at the luminal membrane.*
- **Sodium-glucose cotransporters (SGLTs)** are crucial for glucose reabsorption in the proximal tubule, moving glucose into the cell along with sodium.
- However, glucose cotransport represents a specific mechanism for glucose handling, not the overarching mechanism for sodium reabsorption.
*Sodium reabsorption through countertransport with hydrogen ions at the luminal membrane.*
- The **Na+-H+ exchanger (NHE3)** is significant for exchanging sodium for hydrogen ions at the luminal membrane in the proximal tubule.
- This mechanism is important for **acid-base balance** and some sodium reabsorption, but it is secondary to the Na+-K+-ATPase in driving the overall sodium gradient.
Renal and Non-renal Excretion Indian Medical PG Question 10: Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
- A. Sitagliptin
- B. Vildagliptin
- C. Linagliptin (Correct Answer)
- D. Saxagliptin
Renal and Non-renal Excretion Explanation: ***Linagliptin***
- Unlike other **DPP-IV inhibitors**, **linagliptin** is primarily eliminated via **biliary/fecal excretion** (~85%) rather than renal excretion.
- This unique elimination pathway makes it **safe** for use in patients with **chronic kidney disease** at its usual dose, without the need for dose adjustment.
- It is the **only DPP-IV inhibitor** that does not require dose modification in CKD.
*Sitagliptin*
- **Sitagliptin** is primarily eliminated by the **kidneys** (~80% renal excretion), requiring **significant dose adjustments** in patients with **renal impairment**.
- Without dose modification, there is an increased risk of **drug accumulation** and adverse effects in CKD patients.
*Vildagliptin*
- **Vildagliptin** undergoes **hydrolysis** with subsequent **renal excretion** of inactive metabolites, requiring **dose reduction** in patients with moderate to severe **renal impairment**.
- Not recommended in severe renal impairment (eGFR <50 mL/min).
*Saxagliptin*
- **Saxagliptin** is partially eliminated via **renal excretion** and requires **dose reduction** by 50% in patients with moderate to severe **CKD**.
- Both parent drug and active metabolite accumulate in renal impairment, necessitating dose adjustment.
More Renal and Non-renal Excretion Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
